Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — H1 2020/21 Earnings Presentation
9 slides from Coloplast A/s Class B's earnings presentation, 2021
Slide 1: Coloplast earnings conference call H1 2020/21
Coloplast earnings conference call H1 2020/21 Cartago factory, Costa Rica Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q2 organic growth of 2% and underlying EBIT margin of 33%
Q2 organic growth of 2% and underlying EBIT margin of 33%1) – underlying EBIT margin guidance raised to 32-33% from 31-32% REVENUE GROWTH Q2 Highlights Reported revenue (mDKK) 0% • Organic growth of 2% and -1% reported growth in DKK Organic growth • Chronic Care growth was negatively impacted by DKK
Slide 4: Q2 growth driven by Ostomy Care in Emerging markets, offset by stock building
Q2 growth driven by Ostomy Care in Emerging markets, offset by stock building in comparison period and COVID-19 impact in Europe Q2 20/21 revenue by business area Q2 20/21 revenue by geography Business Reported revenue Q2 Organic growth Organic growth Geographic Reported revenue Q2 Organic growth Or
Slide 5: H1 2020/21 reported revenue declined by 0.5% due to currency depreciation
H1 2020/21 reported revenue declined by 0.5% due to depreciation in USD, GBP and Emerging market currencies H1 Revenue development (DKKm) Comments • H1 2020/21 reported revenue decreased by DKK 44m compared to H1 2019/20 342 4 -389 • H1 organic growth was 4% or DKK 342m • Main drivers of H1 performa
Slide 6: H1 reported EBIT margin of 33% before special items
H1 reported EBIT margin of 33% before special items driven by lower commercial spending due to COVID-19 H1 EBIT margin development (%) Comments • H1 gross margin was 68%, on par with last year 33.5 • Positive impact on the gross margin from Global Operations 1.3 0.1 Plan 4 and 5, partly offset by wa
Slide 7: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments • Free cash flow in H1 2020/21 was DKK 446m compared to DKK 1,181m in H1 2019/20 98 99 98 93 • Adjusting for acquisitions, mainly Nine Continents Medical, the free 90 90 cash flow in H1 was DKK 1,455m, up 23% vs. compari
Slide 8: Organic growth guidance for FY 2020/21 unchanged at 7-8%, EBIT margin guidance raised
Organic growth guidance for FY 2020/21 unchanged at 7-8%, EBIT margin guidance raised to 32-33% before special items GUIDANCE 2020/21 GUIDANCE 2020/21 (DKK)* KEY ASSUMPTIONS • Double-digit growth in the second half of 2020/21 SALES 7-8% • Resumption of elective procedures and hospital activity acros
Slide 9: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /